2017-08-11 16:21:45 UTC

FDA Issues Alert for Liquid-Filled Intragastric Balloon Systems

Aug. 11, 2017

Providers encouraged to report all adverse events to the FDA.

The FDA has issued an update to alert health-care providers of five deaths in patients with liquid-filled instagastric balloon systems— devices used to treat obesity. These devices from these deaths included Orbera Intragastric Balloon System, manufactured by Apollo Endo Surgery, and the ReShape Integrated Dual Balloon System, manufactured by ReShape Medical Inc. Death occurred within a month or less of balloon placement. 

While the root cause of death has not been definitively attributed to the devices or insertion procedures, the FDA recommends that providers closely monitor patients with these devices for complications. 

AGA offers obesity resources for you and your patients including information on safe treatment options.

More on Obesity

Implementing an Obesity Episode: Lessons from a Solo GI Practitioner

Aug. 23, 2017

Get tips and real world experience on implementing a successful obesity program into a solo GI practice.

What is the Best Management Strategy for Patients With NAFLD?

Aug. 8, 2017

It’s essential for physicians to consider patients with non-alcoholic fatty liver disease in a holistic manner. Read more in the AGA Journals blog.

Talking to Patients With NAFLD

July 27, 2017

Five steps to help you approach patients that have non-alcoholic fatty liver disease (NAFLD).